Evidence map›Paper›PMID 38383877›Full record

ReviewIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2024

Uphill battle: Innovation of thiopurine therapy in global inflammatory bowel disease care.

Ahmed B Bayoumy, Chris J J Mulder, Azhar R Ansari, Murray L Barclay, Tim Florin, Marianne Kiszka-Kanowitz, Luc Derijks, Vishal Sharma, Nanne K H de Boer

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
6.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Revisiting thiopurines and therapeutic drug monitoring in IBD: Insights and implications in the Indian context.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026
    Article
  2. Review
  3. Article
  4. Low risk of malignancies with thiopurines in an Indian cohort of patients with Inflammatory bowel disease.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 6 countries.

Ahmed B BayoumyDepartment of Internal Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.ORCID 0000-0002-5302-9312
Chris J J MulderDepartment of Gastroenterology and Hepatology, AGEM Research Institute, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. cjmdl1@gmail.com.
Azhar R AnsariDepartment of Gastroenterology and Hepatology, London Bridge Hospital, London, UK.
Murray L BarclayDepartment of Gastroenterology, Christchurch Hospital, Christchurch, Waitaha - Canterbury, New Zealand.
Tim FlorinMater Research, University of Queensland, Translational Research Institute, South Brisbane, Australia.
Marianne Kiszka-KanowitzCopenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Copenhagen University Hospital - Amager and Hvidovre Hospital, Hvidovre, Denmark.
Luc DerijksDepartment of Clinical Pharmacy, Máxima Medical Center, Veldhoven, The Netherlands.
Vishal SharmaDepartment of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012, India.
Nanne K H de BoerDepartment of Gastroenterology and Hepatology, AGEM Research Institute, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Vrije Universiteit Amsterdam · NLAmsterdam University Medical Centers · NLChristchurch Hospital · NZHvidovre Hospital · DKLondon Bridge Hospital · GBPost Graduate Institute of Medical Education and Research · INRadboud University Nijmegen · NLTranslational Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract that encompasses two major conditions: Crohn's disease (CD) and ulcerative colitis (UC). Historically, IBD has been primarily reported in western countries, but over the past decades, its prevalence is rapidly increasing, especially in lower and middle-income countries (LMICs) such as India and China and also in Sub-Saharan Africa. The prevalence of IBD in LMICs has been the subject of growing concern due to the impact of access to public healthcare and the burden it places on healthcare resources. The classical thiopurines face significant challenges due to cessation of therapy in approximately half of patients within one year due to side effects or ineffectiveness. In this article, we highlight innovating thiopurine treatment for IBD patients in downregulating side effects and improving efficacy.

Indexed as

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesPurinesSulfhydryl CompoundsAzathioprineHumansImmunosuppressive AgentsMercaptopurine2-mercaptopurineAzathioprineImmunosuppressive AgentsMercaptopurinePurinesSulfhydryl CompoundsAllopurinolAzathioprineCrohn’s diseaseInflammatory bowel diseaseMercaptopurineThioguanineThiopurinesUlcerative colitis

Identifiers

PMID38383877
PMCPMC10924016
OpenAlexW4391991699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.